Tag: prostate cancer

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer, either alone or in combination with other treatment modalities. ADT, however, is not without long-term effects, with patients commonly experiencing sexual dysfunction, in addition to conferring an increased risk of cardiovascular events. ADT exposure may also increase...
There is a need for focal therapies for low to intermediate-risk prostate cancers, as whole-gland therapies have many complications without necessarily providing a survival benefit. Irreversible electroporation (IRE), a nonthermal ablative method based on forming nanoscale defects in cell membranes, has been proposed as a possible treatment. In this...
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study Oral live-attenuated polio vaccines (OPV) and injected inactivated polio vaccines IPV) have helped eradicate wild polioviruses. However, there is still a need to develop new vaccines...
1. This study evaluated the effects of post-diagnosis low-dose aspirin on prostate cancer-specific mortality and found no overall benefit. 2. The study did find a modest benefit in patients taking aspirin for at least 5 years after diagnosis. Evidence Rating Level: 2 (Good) Study Rundown: Several recent papers have suggested that regular,...
Association of HLA antigen mismatch with risk of developing skin cancer after solid-organ transplant Immunosuppressive agents reduce the risk of graft rejection in solid-organ transplant recipients. However, immunosuppressive regimens are not without risks, increasing the risk of cancer, a major source of morbidity and mortality. In particular, the risk of...
The optimal duration of androgen suppression therapy with radiotherapy for locally advanced prostate cancer is unknown. In 2018, the French Canadian Prostate Cancer Study (PCS) IV trial showed that 18 months of androgen suppression and radiotherapy is associated with fewer adverse effects than 36 months of the same regimen,...
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial The optimal duration of androgen suppression therapy with radiotherapy for locally advanced prostate cancer is...
1. Among men under 75 years of age with localized prostate cancer, radical prostatectomy was associated with a significant survival benefit compared to watchful waiting. 2. In patients who underwent radical prostatectomy, extracapsular extension and a Gleason score of 8 or 9 were strong indicators of poor prognosis. Evidence Rating Level:...
Several treatment regimens are available for prostate cancer with a Gleason score of 9 or 10. These include radical prostatectomy (RP) with adjuvant external beam radiation therapy (EBRT), androgen deprivation therapy (ADT), or both (MaxRP), as well as a regimen without surgery that includes EBRT, ADT, and brachytherapy (MaxRT)....